New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - metformin hydrochloride 500mg;  ;   - coated tablet - 500 mg - active: metformin hydrochloride 500mg     excipient: magnesium stearate opadry clear oy-29020 povidone water - -treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. -metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents. - adjuvant therapy in insulin dependent diabetes especially if overweight.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dicloxacillin sodium, quantity: 542.4 mg (equivalent: dicloxacillin, qty 500 mg) - capsule, hard - excipient ingredients: titanium dioxide; purified water; magnesium stearate; gelatin; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).,bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin. dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.,important note: when it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase-resistant penicillin

United States - English - NLM (National Library of Medicine)

meijer distribution inc - bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - bacitracin 400 [iu] in 1 g - first aid to help prevent infection in minor: - cuts - scrapes - burns

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - mesalazine 500mg;   - enteric coated tablet - 500 mg - active: mesalazine 500mg   excipient: colloidal silicon dioxide crospovidone hypromellose povidone k90   methacrylic acid - methyl metacrylate copolymer (1:2) iron oxide yellow macrogol 6000   magnesium stearate   microcrystalline cellulose povidone purified talc titanium dioxide triethyl citrate - the treatment of crohn's disease localised to the colon.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - mesalazine 500mg - suppository - 500 mg - active: mesalazine 500mg excipient: cetyl alcohol docusate sodium hard fat - treatment of ulcerative proctitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

centre for advanced medicine - ascorbic acid 500 mg/ml;  ;   - solution for injection - 500 mg/ml - active: ascorbic acid 500 mg/ml     excipient: disodium edetate dihydrate nitrogen sodium bicarbonate sodium hydroxide water for injection - ascor l 500 is indicated for ascorbic acid deficiency. parenteral ascorbic acid supplementation may be necessary in the treatment of scurvy for patients with gastric disorders, for patients with extensive injuries, for surgical patients and others only if their needs cannot be met from normal dietary sources or in patients who cannot take oral vitamins. acute ascorbic acid deficiency may be associated with extensive injuries and other states of extreme stress. vitamin c requirements are also significantly increased in certain diseases and conditions such as tuberculosis, hyperthyroidism, peptic ulcer, neoplastic disease and lactation.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 574mg equivalent to amoxycillin 500 mg;  ; potassium clavulanate 149mg equivalent to clavulanic acid 125 mg;   - film coated tablet - 500mg/125mg - active: amoxicillin trihydrate 574mg equivalent to amoxycillin 500 mg   potassium clavulanate 149mg equivalent to clavulanic acid 125 mg   excipient: croscarmellose sodium ethylcellulose hypromellose magnesium stearate microcrystalline cellulose povidone purified talc   purified water titanium dioxide triethyl citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

New Zealand - English - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - metformin hydrochloride 500mg;  ;   - film coated tablet - 500 mg - active: metformin hydrochloride 500mg     excipient: colloidal silicon dioxide hypromellose e-15 macrogol 6000 magnesium stearate maize starch povidone propylene glycol purified talc purified water sodium starch glycolate titanium dioxide - to control hyperglycaemia in metformin responsive, stable, mild, non-ketosis prone maturity onset type of diabetes (type ii) which cannot be controlled by proper dietary management, exercise and weight reduction or when insulin therapy is not appropriate. it may be used alone or in combination with sulphonylurea therapy. metformin can be of value for the treatment of obese diabetics. it may also be used as adjuvant therapy in insulin-dependent diabetics especially if they are overweight.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - cilastatin sodium 571mg equivalent to 500 mg cilastatin acid. (includes 4.6% overage).; imipenem monohydrate 560mg equivalent to 500 mg imipenem. (includes 4.6% overage).;   - powder for infusion - 500mg/500mg - active: cilastatin sodium 571mg equivalent to 500 mg cilastatin acid. (includes 4.6% overage). imipenem monohydrate 560mg equivalent to 500 mg imipenem. (includes 4.6% overage).   excipient: sodium bicarbonate

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation); fluticasone propionate, quantity: 500 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.